Dicloqualone (SL-164): Methaqualone Analogue Evidence, Sedation & Safety Gaps

Dicloqualone (SL-164): Methaqualone Analogue Evidence, Sedation & Safety Gaps

Quick answer

Dicloqualone, often sold or discussed as SL-164, is a quinazolinone sedative related structurally to methaqualone.

CFSRE confirmed the compound in U.S. drug material and describes sedative pharmacology involving increased GABA-receptor activity.

What is missing is just as important: there is no mature controlled human evidence base defining safe exposure, pharmacokinetics, dependence risk or comparative safety versus methaqualone.

Why people call it a Quaalude analogue

Methaqualone and dicloqualone share the quinazolinone chemical family.

That makes “analogue” chemically reasonable.

But an analogue can differ in receptor activity, metabolism, toxic metabolites, duration and therapeutic index.

So “Quaalude analogue” should not be translated into “same effects with a different legal status.”

What U.S. forensic work has found

CFSRE reported dicloqualone in a drug material submitted from Chicago.

The sample also contained opioids including fentanyl and heroin plus diphenhydramine.

That polysubstance finding is a useful reminder that a sedative detected in the illicit supply may be encountered as part of a mixture rather than as a pure isolated chemical.

What is known about pharmacology

Historical/preclinical pharmacology suggests sedative activity through GABAergic mechanisms.

Modern human pharmacokinetic and toxicological data are sparse.

That makes claims about exact duration, potency or “equivalent” methaqualone effects highly uncertain.

Depressant combinations

Combining a sedative such as dicloqualone with alcohol, benzodiazepines, opioids or other central nervous system depressants can increase impairment and loss of consciousness.

If an opioid is involved, respiratory depression becomes a major emergency risk.

Related evidence

• Novel sedatives & qualone analogues
• 2-Methoxyqualone
• Designer benzodiazepines
• Research chemicals & NPS evidence map

How to interpret the evidence without overreaching

Dicloqualone has a longer chemical history than many newly appearing NPS, but age does not equal a modern clinical evidence base. Historical pharmacology, analytical identification, and contemporary market detection answer different questions. A source that confirms identity or receptor activity does not automatically establish present-day product composition, human dose-response, or the frequency of severe outcomes.

The most defensible way to read the evidence is in layers. Chemical and analytical studies can establish what the molecule is and how laboratories can identify it. Preclinical pharmacology can support a sedative-hypnotic mechanism. Human case reports or toxicology detections, when available, show that real exposure occurs. None of those layers by itself creates a validated safety margin for unregulated material.

Dependence, withdrawal, and prolonged impairment

For sedative-hypnotic compounds, repeated exposure raises concern for tolerance and physical dependence even when molecule-specific withdrawal studies are sparse. The exact onset, severity, and duration of withdrawal from dicloqualone have not been established well enough to support a fixed timeline or self-taper conversion. Severe or escalating symptoms after stopping a regularly used sedative deserve medical assessment rather than an internet-derived schedule.

Likewise, subjective recovery from intoxication does not prove that psychomotor function has fully normalized. Unknown formulation strength, co-ingestants, and individual metabolism can make impairment difficult to predict.

Testing and counterfeit uncertainty

Novel sedatives may be missed by routine screening panels. Definitive identification may require mass-spectrometric testing and an updated laboratory library. This matters when a product is sold under a familiar sedative name: branding, tablet appearance, or seller description cannot establish that dicloqualone is actually present or that it is the only active compound.

For harm reduction, the evidence boundary is therefore as important as the evidence itself: known sedative-class hazards should be visible, while unsupported potency rankings, equivalence charts, and precise withdrawal schedules should stay out.

Bottom line

Dicloqualone is a real, analytically confirmed RC sedative—not merely an internet legend.

But the human evidence is too thin to support the confident “modern Quaalude” framing often seen in community discussion.